Redefining the ‘E’ in EBM

Abstract

hta/ 108001#/).TJ is also in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews.TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products.In 2011-2014, TJ acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada.He has acted as a consultant for Roche (1997-1999), GSK (2001-2002), Sanofi-Synthelabo (2003) and IMS Health (2013).In 2014-2016, TJ was a member of three advisory boards for Boehringer Ingelheim.TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 12 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.